ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alkermes plc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
Alkermes plc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $1.18B | $1.08B | $920.00M | $777.55M | $627.42M | $551.76M | $524.50M | $450.33M | $362.83M | $256.15M | 80.3% | +9.3% |
| VIVITROL | $467.91M | $457.32M | $400.42M | $379.48M | $343.85M | $310.72M | $335.37M | $302.61M | $269.32M | $208.98M | 31.7% | +2.3% |
| ARISTADA and ARISTADA INITIO | $370.04M | $346.19M | $327.69M | $302.05M | $275.36M | $241.04M | $189.13M | $147.73M | – | – | 25.1% | +6.9% |
| LYBALVI | $346.69M | $280.03M | $191.89M | $96.02M | $8.22M | – | – | – | – | – | 23.5% | +23.8% |
| Manufacturing and royalty revenues | $291.26M | $474.10M | $743.39M | $331.98M | $541.81M | $484.00M | $447.88M | $526.68M | $505.31M | $487.25M | 19.7% | -38.6% |
| Royalty | $245.26M | $354.67M | $600.89M | $219.61M | $436.18M | $364.97M | $343.63M | $393.65M | $352.49M | – | 16.6% | -30.8% |
| Manufacturing Revenue | $46.00M | $119.43M | $142.50M | $112.37M | $105.63M | $119.03M | $104.25M | $133.03M | $152.82M | – | 3.1% | -61.5% |
| Research and development revenue | – | $3.00K | $19.00K | $260.00K | $1.02M | $1.95M | $52.82M | $68.90M | $7.23M | $2.30M | – | – |
| ARISTADA | – | – | – | – | – | – | – | $147.73M | $93.51M | $47.16M | – | – |
| License revenue | – | – | – | $2.00M | $3.50M | $1.05M | $145.75M | $48.37M | $28.00M | – | – | – |
| ARISTADA/ARISTADA INITIO | – | – | – | – | – | – | $189.13M | $147.73M | $93.51M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.37B | $1.41B | $1.49B | $931.99M | $984.24M | $839.00M | $966.93M | $884.60M | $700.09M | $557.31M | 93.0% | -2.7% |
| Rest of world | $102.36M | $146.18M | $170.29M | $177.98M | $187.34M | $196.53M | $200.82M | $204.76M | $193.58M | $183.98M | 6.9% | -30.0% |
| Ireland | $754.00K | $1.29M | $1.18M | $1.83M | $2.18M | $3.23M | $3.20M | $4.92M | $9.71M | $4.41M | 0.1% | -41.7% |
| EU | – | – | – | $750.00M | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Alkermes's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.